There are two treatment approaches to help manage some of the signs and
symptoms of Gaucher disease type 1—enzyme replacement or substrate
reduction—that both achieve the goal of reducing excess GL-1.
If you have been diagnosed with Gaucher disease type 1, treatment approaches are available to help manage certain signs and symptoms of the disease. The goal of these treatments is to reduce or prevent the buildup of GL-1. Treatment outcomes may vary among patients.
Two treatment approaches for Gaucher disease type 1:
Talk to your doctor about treatment options; your doctor will decide what treatment is right for you.
Cerezyme is the ONLY ERT that has been prescribed for over 25 years.
Cerezyme® (imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions:
Hypersensitivity and Infusion-Associated Reactions: Serious allergic reactions (anaphylaxis) have been reported in patients treated with Cerezyme. Symptoms suggestive of an allergic reaction have been reported during or shortly after an infusion and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), rapid heart rate, and low blood pressure. Inform your doctor and seek medical care if you experience any of these symptoms. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.
Immune Responses: Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies.
Adverse reactions reported in adults include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting.
Adverse reactions reported in pediatric patients 2 years of age and older are similar to adults.
Please see the Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Medical Information at 1-800-745-4447, Option 2.